Completed PHASE3 INTERVENTIONAL 2-arm NCT01217476

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study (TRANS-North)

A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment With Trafermin 0.01% Spray in Patients With Diabetic Foot Ulcer of Neuropathic Origin

Sponsor: Olympus Biotech Corporation

Conditions Diabetic Foot Ulcer of Neuropathic Origin

Interventions Trafermin 0.01% spray

Updated 6 times since 2017 Last updated: Aug 4, 2014 Started: Dec 31, 2010 Primary completion: May 31, 2012 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetic Foot Ulcer of Neuropathic Origin, this trial is completed. The trial is conducted by Olympus Biotech Corporation and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Olympus Biotech Corporation

Data source: Olympus Biotech Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Almelo, Netherlands , Amsterdam, Netherlands , Apeldoorn, Netherlands , Bad Mergentheim, Germany , Bad Nauheim, Germany , Brussels, Belgium , Budapest, Hungary , Cologne, Germany , Crikvenica, Croatia and 23 more locations